Goldman Sachs’s Precigen PGEN Stock Holding History

Goldman Sachs’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-46,000	Closed	-$301K	–	5373
2018 Q4	$301K	Hold	46,000	–	–	﹤0.01%	4634
2018 Q3	$792K	Hold	46,000	–	–	﹤0.01%	4178
2018 Q2	$641K	Buy	+46,000	New	+$777K	﹤0.01%	4365
2016 Q4	–	Sell	-294,426	Closed	-$8.18M	–	7027
2016 Q3	$8.18M	Sell	294,426 -623,764	-68%	-$16.5M	﹤0.01%	2619
2016 Q2	$22.4M	Buy	918,190 +877,830	+2,175%	+$24.9M	0.01%	1713
2016 Q1	$1.36M	Hold	40,360	–	–	﹤0.01%	3815
2015 Q4	$1.21M	Buy	40,360 +13,117	+48%	+$442K	﹤0.01%	4114
2015 Q3	$859K	Buy	+27,243	New	+$1.33M	﹤0.01%	4619
2015 Q1	–	Sell	-209	Closed	-$6K	–	7226
2014 Q4	$6K	Buy	+209	New	+$4.58K	﹤0.01%	7062

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Goldman Sachs's PGEN Position: Q1 2026 in Review

Goldman Sachs increased its Precigen (PGEN) stake by 54% in Q1 2026, buying an estimated $4.83M and bringing the position to 3,350,477 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

Goldman Sachs first reported a position in PGEN in Q3 2013 and has held it in 49 quarters since. 205 funds tracked by Wall St. Rank hold PGEN as of Q1 2026.

Goldman Sachs held 3,350,477 shares of Precigen worth $13M as of Q1 2026.
Goldman Sachs bought 1,176,544 Precigen shares in Q1 2026, an estimated $4.83M.
Precigen made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2839 holding.
Goldman Sachs first reported a position in Precigen in Q3 2013 and has held it in 49 quarters since.
205 funds tracked by Wall St. Rank held Precigen as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.